San Diego, California – The recent approval by the Food and Drug Administration of a new nasal spray flu vaccine marks a significant milestone in the fight against influenza. This innovative vaccine, known as FluMist, offers a convenient alternative to traditional flu shots, allowing individuals to self-administer the vaccine or have caregivers administer it to them.
FluMist, which has been in use for over two decades, contains live-attenuated flu virus and is delivered via a nasal spray rather than an injection. Despite containing a weakened form of the virus, the nasal spray vaccine is not known to cause influenza illness. Studies have shown that FluMist is as effective as the flu shot, with an efficacy rate of around 45%.
One of the key advantages of FluMist is its ease of administration, making it a promising option for individuals who may have reservations about needles. The vaccine is approved for use in individuals between the ages of 2 and 49, providing a valuable alternative for those seeking a different method of flu prevention.
While the at-home version of FluMist is expected to be available for the next flu season, individuals can currently receive the vaccine at pharmacies and doctor’s offices. The accessibility of a self-administered flu vaccine has the potential to increase vaccination rates, particularly among individuals who may be hesitant to receive traditional flu shots.
Experts emphasize the safety of live-attenuated virus vaccines such as FluMist, highlighting that the virus does not replicate in the lungs where it could cause infection. Common side effects of FluMist include a runny nose, nasal congestion, fever in children, and sore throat in adults.
Overall, the approval of at-home FluMist represents a significant advancement in influenza prevention and has the potential to improve vaccination rates, particularly among vulnerable populations. As the world continues to navigate the challenges of the COVID-19 pandemic, innovations in vaccine delivery methods offer hope for a healthier future for all.